Evidence map›Paper›PMID 40475782›Full record

ReviewFrontiers in immunology2025

Tumor-infiltrating lymphocytes in cancer immunotherapy: from chemotactic recruitment to translational modeling.

Fatjona Pupuleku Kraja, Vladimir B Jurisic, Altijana Hromić-Jahjefendić, Nafsika Rossopoulou, Theodora Katsila, Katarina Mirjacic Martinovic, Javier De Las Rivas, Carmen Cristina Diaconu, Árpád Szöőr

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Lnk Governs chemokine-directed trafficking of CD8Molecular therapy. Oncology · 2026
    Article
  4. Review
  5. Article
  6. Review
  7. Observational
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Fatjona Pupuleku Kraja *Oncology Clinic, University Hospital Center Mother Teresa, Tirana, Albania.
Vladimir B Jurisic *Institute of Pathophysiology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
Altijana Hromić-Jahjefendić *Department of Genetics and Bioengineering, Faculty of Engineering and Natural Sciences, International University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
Nafsika RossopoulouInstitute of Chemical Biology, National Hellenic Research Foundation, Athens, Greece.
Theodora KatsilaInstitute of Chemical Biology, National Hellenic Research Foundation, Athens, Greece.
Katarina Mirjacic MartinovicLaboratory of Immunology, Department of Experimental Oncology, Institute of Oncology and Radiology of Serbia, Belgrade, Serbia.
Javier De Las RivasBioinformatics and Functional Genomics Group, Cancer Research Center (CiC-IBMCC, CSIC/USAL), Consejo Superior de Investigaciones Cientificas (CSIC) and University of Salamanca (USAL), Salamanca, Spain.
Carmen Cristina DiaconuDepartment of Cellular and Molecular Pathology, Stefan S. Nicolau Institute of Virology, Bucharest, Romania.
Árpád SzöőrDepartment of Biophysics and Cell Biology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor-infiltrating lymphocytes (TILs) are a diverse population of immune cells that play a central role in tumor immunity and have emerged as critical mediators in cancer immunotherapy. This review explores the phenotypic and functional diversity of TILs-including CD8

Indexed as

Chemotaxis, LeukocyteImmunotherapyLymphocytes, Tumor-InfiltratingNeoplasmsAnimalsHumansTranslational Research, BiomedicalTumor Microenvironmentadoptive cell transferexperimental modelsimmunotherapytumor-infiltrating lymphocytestumor microenvironment

Identifiers

PMID40475782
PMCPMC12137109

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.